Table 1 General characteristics of the study population (n = 628)
From: Association between inpatient glycemic variability and COVID-19 mortality: a prospective study
Characteristics | Values |
|---|---|
Age (mean ± SD) | 59.62 ± 15.899 |
Male gender | 413 (65.8%) |
Comorbidities | |
Hypertension | 328 (52.2%) |
Diabetes mellitus | 206 (32.8%) |
Cardiovascular disease | 85 (13.5%) |
Cerebrovascular disease | 21 (3.34%) |
Chronic kidney disease | 24 (3.8%) |
Malignancy | 27 (4.3%) |
Dyslipidemia | 174 (27.7%) |
Obesity* | 200 (n = 625) (32%) |
Pulmonary disease | 55 (8.8%) |
Dexamethasone** | 586 (93.3%) |
Laboratory findings (median/IQR) | |
WBC count (× 103 cells/µL) | 7.7 (5.7–10.6) |
Lymphocytes (/µL) | 11 (7–16.75) |
Platelets (× 103 cells/µL) | 187.5 (147–238) |
CRP (mg/dL) | 85.05 (40.25–153.88) |
Creatinine (mg/dL) | 0.91 (0.74–1.1) |
Neutrophils-lymphocytes ratio | 7.5 (4.5–12.9) |
Hypoglycemia | 59 (9.4%) |
ICU admission | 374 (59.6%) |
Mechanical ventilation | 229 (36.5%) |
Acute renal failure | 67 (10.7%) |
Length of stay (median, IQR) | 10 (6–18.8) |
Mortality | 131 (20.9%) |